US20110137056A1 - Chemical Process For Preparation Of Intermediates - Google Patents

Chemical Process For Preparation Of Intermediates Download PDF

Info

Publication number
US20110137056A1
US20110137056A1 US12/956,133 US95613310A US2011137056A1 US 20110137056 A1 US20110137056 A1 US 20110137056A1 US 95613310 A US95613310 A US 95613310A US 2011137056 A1 US2011137056 A1 US 2011137056A1
Authority
US
United States
Prior art keywords
compound
formula
process according
preparing
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/956,133
Inventor
Jean-Paul Dejonghe
Koen Peeters
Marc Renard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20110137056(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to US12/956,133 priority Critical patent/US20110137056A1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER FROM 11/833,263 PREVIOUSLY RECORDED ON REEL 025853 FRAME 0251. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT APPLICATION NUMBER IS 12/956133. Assignors: PEETERS, KOEN, DEJONGHE, JEAN-PAUL, RENARD, MARC
Publication of US20110137056A1 publication Critical patent/US20110137056A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/24Preparation of carboxylic acid esters by reacting carboxylic acids or derivatives thereof with a carbon-to-oxygen ether bond, e.g. acetal, tetrahydrofuran
    • C07C67/26Preparation of carboxylic acid esters by reacting carboxylic acids or derivatives thereof with a carbon-to-oxygen ether bond, e.g. acetal, tetrahydrofuran with an oxirane ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/08Compounds containing oxirane rings with hydrocarbon radicals, substituted by halogen atoms, nitro radicals or nitroso radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/143Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40Halogenated unsaturated alcohols
    • C07C33/46Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/753Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D301/00Preparation of oxiranes
    • C07D301/02Synthesis of the oxirane ring
    • C07D301/24Synthesis of the oxirane ring by splitting off HAL—Y from compounds containing the radical HAL—C—C—OY
    • C07D301/26Y being hydrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Definitions

  • the present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals.
  • the present invention concerns enantiomerically pure trans-cyclopropane carboxylic acid derivatives, processes for preparing the carboxylic acid derivatives and their use in preparing pharmaceuticals.
  • the present invention provides processes for preparing a compound of formula IV
  • R is an alkyl group, comprising: treating a compound of formula III
  • R 1 and R 2 are, independently, alkyl.
  • the present invention also provides processes for preparing a compound of formula IV
  • R is an alkyl group, comprising: a) reducing a compound of formula I
  • R 1 and R 2 are, independently, selected from alkyl.
  • R is an alkyl group, comprising: a) treating the compound of formula II
  • R 1 and R 2 arc, independently, selected from alkyl.
  • the present invention also provides processes for preparing a compound of formula VII
  • the present invention also provides a compound of formula II
  • R is an alkyl group
  • suitable values of R include, but arc not limited to, for example, (C 1-6 )alkyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, and tert-butyl. In some embodiments, R is ethyl.
  • the compound of formula IV may be prepared from a compound of formula II
  • the compound of formula I is reduced to the compound of formula II.
  • the reduction is carried out using a suitable reducing agent.
  • suitable reducing agents will include those which are able to reduce the carbonyl group in the compound of formula I to the hydroxyl group of formula II and give an enantiometric excess of the compound of formula II with the stereo chemistry shown in formula II.
  • suitable conditions include, for example, catalytic reduction or use of a transition metal with chiral ligand.
  • a particular example of a suitable reducing agent is oxazaborolidine which may be formed by mixing trimethoxy borane and S-diphenylprolinol, followed by addition of borane dimethylsulphide. This is generally carried out in an inert solvent such as toluene.
  • the temperature is conveniently maintained at a temperature in the range 25 to 45° C., for example 35 to 40° C.
  • the compound of formula I is treated with the reducing agent so formed. This is generally carried out in an inert solvent such as toluene.
  • the temperature is conveniently maintained at a temperature in the range 25 to 45° C., for example 35 to 40° C.
  • a compound of formula IV may be prepared by treating a compound of formula III
  • R 1 and R 2 are, independently, selected from alkyl such as (C 1-6 )alkyl.
  • a suitable 25 compound of formula 3 is triethyl phosphonoacetate.
  • the reaction is generally carried out in an inert solvent such as toluene.
  • the reaction is generally carried out at a temperature in the range 30 to 80° C., conveniently 40 to 60° C., e.g. 40° C.
  • the reaction may conveniently be carried out in the presence of a base.
  • suitable bases include, but are not limited to, sodium hydride and alkali metal (for example potassium or sodium) alkoxides (for example t-butoxide). Specific examples are potassium and sodium t-butoxide.
  • the compound of formula III may be prepared by treating the compound of formula II with a base, such as an alkali metal hydroxide, for example sodium hydroxide. This is conveniently carried out in a suitable solvent such as water.
  • a base such as an alkali metal hydroxide, for example sodium hydroxide.
  • the compound of formula II may be converted to a compound of formula IV via the compound of formula III,
  • the compound of formula II is converted to a compound of formula IV by treating the compound of formula II with a base, such as sodium hydride. This is generally carried out in an inert solvent such as toluene. This is treated with triethyl phosphonoacetate. This is generally carried out at a temperature in the range 30 to 80° C., conveniently 40 to 60° C., e.g. 40° C.
  • the present invention also provides processes for preparing a compound of formula VII
  • Suitable bases include, but are not limited to, alkali metal alkoxides such as potassium methoxide or sodium methoxide.
  • An agent such as methyl formiate may also be present.
  • the reaction is generally carried out in a suitable solvent such as an alcohol in a suitable solvent. In one embodiment, the reaction is carried out in toluene and methanol.
  • a compound of formula IV may be treated with the base and then treated with ammonia.
  • the reaction is under pressure during the treatment with ammonia.
  • An example of a suitable pressure is 2 to 10 bar.
  • the reaction may be carried out at an elevated temperature, such as 40 to 70° C., for example at about 60° C.
  • the present invention is also directed to compounds of formula IV and VII.
  • the present invention also provides novel intermediates of formula II, III, or VII.
  • Aluminium trichloride (210.2 g) was added to 1,2-difluorobenzene (200.0 g) at room temperature. The obtained slurry was heated to 50° C., then chloroacetyl chloride (198.0 g) was added over 50 minutes. The reaction mixture was stirred for an additional 60 minutes, then added slowly to a mixture of ice (786.0 g), water (196.0 g) and 37 wt % hydrochloric acid (297.0 g), during the addition the temperature was kept below 60° C. After the addition, 20 the reaction mixture was heated to 60° C. and the layers separated. The organic layer was washed twice with a 20 w/v% sodium chloride solution (200.0 mL). 2-Chloro-1-(3,4-difluorophenyl)ethanone (270.2 g) was obtained by vacuum distillation of the organic layer.
  • Trimethoxy borane (2.7 g) was added at room temperature to a stirred solution of S-diphenylprolinol (4.7 g) in toluene (128.6 mL). After stirring this mixture for 90 minutes at 40° C. borane dimethylsulfide (22.3 g) was added over 15 minutes maintaining the temperature between 35 and 45° C. This mixture was stirred for 60 minutes at 40° C., then a solution of 2-chloro-1-(3,4-difluorophenyl)ethanone (70.0 g) in toluene (184.1 mL) was dosed over a period of 120 minutes maintaining the temperature between 35 and 45° C.
  • the product in solution was characterized by mass spectroscopy (APCI).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)

Abstract

The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure trans-cyclopropane carboxylic acid derivatives, processes for preparing the carboxylic acid derivatives and their use in preparing pharmaceuticals.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority to Great Britain Application No. 0615619.4 filed 5 Aug. 5, 2006, which is incorporated herein by reference in its entirety.
  • FIELD OF THE INVENTION
  • The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure trans-cyclopropane carboxylic acid derivatives, processes for preparing the carboxylic acid derivatives and their use in preparing pharmaceuticals.
  • BACKGROUND OF THE INVENTION
  • The compound [1S-(1α, 2α, 3β(3S*,2R*),5 β)]-3-[7-[2-(3,4-difluorophenyl)-cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol (Compound A), and similar such compounds, are disclosed in WO 00/34283 and WO 99/05143. These compounds are disclosed as P2T (which is now usually referred to as P2Y12) receptor antagonists. Such antagonists can be used as, inter alia, inhibitors of platelet activation, aggregation or degranulation.
  • We have now found an advantageous process for preparing enantiomerically pure trans-cyclopropane carboxylic acid derivatives which may be used in the preparation of Compound A. The process offers advantages such as, for example: diastereoselecivity, enantioselectivity, high yield, potential for manufacturing (e.g. reagents and procedures suitable for large scale production, non-hazardous reagents, less waste).
  • SUMMARY OF THE INVENTION
  • The present invention provides processes for preparing a compound of formula IV
  • Figure US20110137056A1-20110609-C00001
  • wherein R is an alkyl group, comprising: treating a compound of formula III
  • Figure US20110137056A1-20110609-C00002
  • with a compound of formula 3
  • Figure US20110137056A1-20110609-C00003
  • wherein R1 and R2 are, independently, alkyl.
  • The present invention also provides processes for preparing a compound of formula IV
  • Figure US20110137056A1-20110609-C00004
  • wherein R is an alkyl group, comprising: a) reducing a compound of formula I
  • Figure US20110137056A1-20110609-C00005
  • to give a compound of formula II
  • Figure US20110137056A1-20110609-C00006
  • b) treating the compound of formula II with a base to give a compound of formula III
  • Figure US20110137056A1-20110609-C00007
  • and c) treating the compound of formula III with a compound of formula 3
  • Figure US20110137056A1-20110609-C00008
  • wherein R1 and R2 are, independently, selected from alkyl.
      • The present invention also provides processes for preparing a compound of formula IV
  • Figure US20110137056A1-20110609-C00009
  • wherein R is an alkyl group, comprising: a) treating the compound of formula II
  • Figure US20110137056A1-20110609-C00010
  • with a base; and b) treating the product of a) with a compound of formula 3
  • Figure US20110137056A1-20110609-C00011
  • wherein R1 and R2 arc, independently, selected from alkyl.
  • The present invention also provides processes for preparing a compound of formula VII
  • Figure US20110137056A1-20110609-C00012
  • comprising treating the compound of formula IV
  • Figure US20110137056A1-20110609-C00013
  • with ammonia in the presence of a suitable base.
  • The present invention also provides a compound of formula II
  • Figure US20110137056A1-20110609-C00014
  • or formula III
  • Figure US20110137056A1-20110609-C00015
  • or formula VII
  • Figure US20110137056A1-20110609-C00016
  • DESCRIPTION OF EMBODIMENTS
  • According to a first aspect of the present invention there is provided one or more compounds of formula IV
  • Figure US20110137056A1-20110609-C00017
  • wherein R is an alkyl group.
  • For any of the embodiments described herein, suitable values of R include, but arc not limited to, for example, (C1-6)alkyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, and tert-butyl. In some embodiments, R is ethyl.
  • The compound of formula IV may be prepared from a compound of formula II
  • Figure US20110137056A1-20110609-C00018
  • According to a further aspect of the present invention there is provided processes for preparing one or more compounds of formula II from a compound of formula I.
  • Figure US20110137056A1-20110609-C00019
  • The compound of formula I is reduced to the compound of formula II. The reduction is carried out using a suitable reducing agent. Suitable reducing agents will include those which are able to reduce the carbonyl group in the compound of formula I to the hydroxyl group of formula II and give an enantiometric excess of the compound of formula II with the stereo chemistry shown in formula II. Examples of suitable conditions include, for example, catalytic reduction or use of a transition metal with chiral ligand.
  • A particular example of a suitable reducing agent is oxazaborolidine which may be formed by mixing trimethoxy borane and S-diphenylprolinol, followed by addition of borane dimethylsulphide. This is generally carried out in an inert solvent such as toluene. The temperature is conveniently maintained at a temperature in the range 25 to 45° C., for example 35 to 40° C.
  • The compound of formula I is treated with the reducing agent so formed. This is generally carried out in an inert solvent such as toluene. The temperature is conveniently maintained at a temperature in the range 25 to 45° C., for example 35 to 40° C.
  • A compound of formula IV may be prepared by treating a compound of formula III
  • Figure US20110137056A1-20110609-C00020
  • with a compound of formula 3
  • Figure US20110137056A1-20110609-C00021
  • wherein R1 and R2 are, independently, selected from alkyl such as (C1-6)alkyl. A suitable 25 compound of formula 3 is triethyl phosphonoacetate.
  • The reaction is generally carried out in an inert solvent such as toluene. The reaction is generally carried out at a temperature in the range 30 to 80° C., conveniently 40 to 60° C., e.g. 40° C. The reaction may conveniently be carried out in the presence of a base. Examples of suitable bases include, but are not limited to, sodium hydride and alkali metal (for example potassium or sodium) alkoxides (for example t-butoxide). Specific examples are potassium and sodium t-butoxide.
  • The compound of formula III may be prepared by treating the compound of formula II with a base, such as an alkali metal hydroxide, for example sodium hydroxide. This is conveniently carried out in a suitable solvent such as water.
  • The compound of formula II may be converted to a compound of formula IV via the compound of formula III,
  • Figure US20110137056A1-20110609-C00022
  • without isolation of the compound of formula III.
  • In a particular embodiment of the present invention, the compound of formula II is converted to a compound of formula IV by treating the compound of formula II with a base, such as sodium hydride. This is generally carried out in an inert solvent such as toluene. This is treated with triethyl phosphonoacetate. This is generally carried out at a temperature in the range 30 to 80° C., conveniently 40 to 60° C., e.g. 40° C.
  • The present invention also provides processes for preparing a compound of formula VII
  • Figure US20110137056A1-20110609-C00023
  • which comprises treating a compound of formula IV with ammonia in the presence of a suitable base. Suitable bases include, but are not limited to, alkali metal alkoxides such as potassium methoxide or sodium methoxide. An agent such as methyl formiate may also be present. The reaction is generally carried out in a suitable solvent such as an alcohol in a suitable solvent. In one embodiment, the reaction is carried out in toluene and methanol.
  • A compound of formula IV may be treated with the base and then treated with ammonia. Preferably, the reaction is under pressure during the treatment with ammonia. An example of a suitable pressure is 2 to 10 bar. The reaction may be carried out at an elevated temperature, such as 40 to 70° C., for example at about 60° C.
  • The present invention is also directed to compounds of formula IV and VII.
  • The present invention also provides novel intermediates of formula II, III, or VII.
  • Any of the embodiments described herein can be combined with any of the other embodiments described herein.
  • In order that the invention disclosed herein may be more efficiently understood, examples are provided below. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting the invention in any manner.
  • EXAMPLES Example 1 Preparation of 2-chloro-1-(3,4-difluorophenyl)ethanone
  • Aluminium trichloride (210.2 g) was added to 1,2-difluorobenzene (200.0 g) at room temperature. The obtained slurry was heated to 50° C., then chloroacetyl chloride (198.0 g) was added over 50 minutes. The reaction mixture was stirred for an additional 60 minutes, then added slowly to a mixture of ice (786.0 g), water (196.0 g) and 37 wt % hydrochloric acid (297.0 g), during the addition the temperature was kept below 60° C. After the addition, 20 the reaction mixture was heated to 60° C. and the layers separated. The organic layer was washed twice with a 20 w/v% sodium chloride solution (200.0 mL). 2-Chloro-1-(3,4-difluorophenyl)ethanone (270.2 g) was obtained by vacuum distillation of the organic layer.
  • Spectral data:
  • 1H-NMR of 2-chloro-1-(3,4-difluorophenyl)ethanone in CDCl3, 300 mHz
  • δ (ppm) H Pattern
    4.7 ClCH2 S
    7.3 Ph H-5 d × d × d × d
    7.8 Ph H-6 M
    Ph H-2
  • 13C-NMR of 2-chloro-1-(3,4-difluorophenyl)ethanone in CDCl3, 75 MHz
  • δ (ppm) Assignment
    45.7 ClCH2CO
    118.4 Ph C-2 and C-5, small JF-C visible
    126.2 Ph C-6, small JF-C visible
    131.6 Ph C-1, small JF-C visible
    149.1-156.3 Ph C-3 and C-4, large JF-C visible
    189.3 ClCH2COPh
  • Example 2 Preparation of 2-chloro-1-S-(3,4-difluorophenyl)ethanol
  • Trimethoxy borane (2.7 g) was added at room temperature to a stirred solution of S-diphenylprolinol (4.7 g) in toluene (128.6 mL). After stirring this mixture for 90 minutes at 40° C. borane dimethylsulfide (22.3 g) was added over 15 minutes maintaining the temperature between 35 and 45° C. This mixture was stirred for 60 minutes at 40° C., then a solution of 2-chloro-1-(3,4-difluorophenyl)ethanone (70.0 g) in toluene (184.1 mL) was dosed over a period of 120 minutes maintaining the temperature between 35 and 45° C. After the completion of the addition, the reaction mixture was stirred for another 60 minutes at 40° C., then cooled to 10° C. Methanol (69.7 g) was added over a period of 20 minutes controlling the gas formation and the temperature to a maximum of 35° C. After the addition the mixture was cooled to 20° C., it was stirred at this temperature for 30 minutes. The obtained solution was then distilled, under reduced pressure at maximum 45° C., until the residual methanol and trimethoxyborane was less than 2 wt %. The obtained solution in toluene was then washed four times with a 10 wt % aqueous HOAc (280.0 mL) at 45 to 55° C. and the obtained water layer back extracted with toluene (140.0 mL). Both organic layers were combined and washed with water (140.0 mL). The resulting organic layer was azeotroped until less than 0.4 wt % water. After correction with toluene, a 33 wt % solution of 2-chloro-1-S-(3,4-difluorophenyl)ethanol was obtained (214.4 g theoretical yield).
  • The product in solution was characterized by mass spectroscopy (EI):
  • M/z Identification
    175.6 M+—H2O
    143.6 M+—CH2Cl
  • Example 3 Preparation of ethyl (1R,2R)-trans 2-(3,4-difluorophenyl) cyclopropyl carboxylate
  • Sodium hydride (13.4 g) was suspended in toluene (119.9 mL) and the resulting slurry heated to 40° C. Then a solution of triethyl phosphonoacetate (38.4 g) in toluene (60.0 mL) was added over a period of 60 minutes keeping the temperature between 40 and 45° C. When the addition was complete, the reaction mixture was stirred for an additional 60 minutes at 40° C. Then 90.9 g of a 33 wt % solution of 2-chloro-1-S-(3,4-difluorophenyl)ethanol in toluene was added over a period of 35 minutes allowing the temperature to raise to maximum 60° C. Once the addition was complete, the obtained mixture was stirred for an additional 14 hours at 60° C. Then water (155.8 mL) was added and the phases separated at 60° C. The toluene solution containing ethyl (1R,2R)-trans 2-(3,4-difluorophenyl) cyclopropyl carboxylate was used as such in the next step.
  • The product in solution was characterized by mass spectroscopy (EI):
  • m/z Identification
    226.3 M+.
    198.3 M+.—H2C═CH2
    180.4 M+.—HOCH2CH3
    153.7 F2PhCH2CH2CH2 +.
    127.4 F2Ph+.
  • Example 4 Preparation of (1R,2R)-trans 2-(3,4-difluorophenyl) cyclopropyl carboxamide
  • Starting from 2-chloro-1-S-(3,4-difluorophenyl)ethanol (30.9 g), ethyl (1R,2R)-trans 2-(3,4-difluorophenyl) cyclopropyl carboxylate was prepared as in example 3. The solvent was distilled and to the resulting oil methanol (109.0 mL), methyl formiate (7.2 g) and 30 wt % sodium methoxide in methanol (11.5 g) were added at room temperature. The mixture was heated to 60° C. in a closed reactor. Then 2 bar NH3-pressure was applied. During a period of 4 hours, the temperature was maintained at 60° C. and the pressure at 2 bar. Then the reactor was cooled to room temperature and vented. The reaction mixture was heated to 60° C. and water (277.2 mL) dosed over 1 hour, the temperature was maintained at 60° C. The 25 resulting solution was cooled to room temperature, then filtered and washed with 1/1 methanol/water (69.3 mL), then with water (49.5 mL) and finally with DiPE (49.5 mL). The resulting crystals were dried at 50° C. in a vacuum oven. After drying, (1R,2R)-trans 2(3,4-difluorophenyl) cyclopropyl carboxamide (22.8 g) was obtained.
  • Spectral data:
  • 1H NMR of (1R,2R)-trans 2-(3,4-difluorophenyl) cyclopropyl carboxamide
  • δ (ppm) H Pattern
    1.2 CH (from CH2) d × d × d
    1.6 CH (from CH2) d × d × d
    and CH—CONH2
    2.5 CH—Ph d × d × d
    5.8 NH2
    6.8-7.1 3 × Ph—H M
  • 13C NMR of (1R,2R)-trans 2-(3,4-difluorophenyl) cyclopropyl carboxamide
  • δ (ppm) Assignment
    16.7 CH2
    25.0 C—CONH2 or C—Ph
    26.1 C—Ph or C—CONH2
    115.3 Ph C-2, 2JF-C: 17.6 Hz
    117.6 Ph C-5, 2JF-C: 17.4 Hz
    122.7 Ph C-6, 3JF-C: 6.0 Hz and 4JF-C: 3.5
    135-155 Ph C-4 and C-3
    174.3 CONH2
  • Example 5 Preparation of (1R, 2S)2-(3,4-difluorophenyl)-cyclopropane amine
  • (1R,2R)-trans 2-(3,4-difluorophenyl) cyclopropyl carboxamide (25.0 g) and 157.4 g of a 30 wt % solution of NaOH were mixed and heated to 20 to 25° C. A 26 wt % solution of aqueous NaOCl (89.5 g) was dosed over a period of 30 minutes maintaining the temperature below 33° C. Once the addition was finished, the reaction mixture was stirred for an additional 3 hours at 30 to 33° C. The resulting mixture was then heated to 60° C. and stirred at this temperature for an additional 20 minutes.
  • After cooling to 5° C., the pH of the reaction mixture was corrected with HC137 wt % (99.1 g) until a pH of 8.5-9.5 was achieved. iPrOAc (153.3 mL) and MeOH (85.0 mL) were added, followed by water (33.8 mL), after stirring and decantation the phases were separated. The obtained water layer was extracted twice with iPrOAc (75.0 and 55.0 mL respectively). The combined organic phases were diluted until a concentration of 5 wt % was achieved. The obtained solution contains (1R, 2S)2-(3,4-difluorophenyl)-cyclopropane amine (18.0 g in 360.4 g solution).
  • The product in solution was characterized by mass spectroscopy (APCI).
  • m/z Identification
    210.6 MH+ + CH3CN
    169.9 MH+
    153.2 MH+ − NH3
  • Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference (including, but not limited to, journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, and the like) cited in the present application is incorporated herein by reference in its entirety.

Claims (21)

1. A process for preparing a compound of formula IV
Figure US20110137056A1-20110609-C00024
wherein R is an alkyl group, comprising:
treating a compound of formula III
Figure US20110137056A1-20110609-C00025
with a compound of formula 3
Figure US20110137056A1-20110609-C00026
wherein R1 and R2 are, independently, alkyl.
2. A process according to claim 1 wherein the compound of formula 3 is triethyl phosphonoacetate.
3. A process according to claim 1 wherein R, R1, and R2 are, independently, selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, and tert-butyl.
4. A process according to claim 1 further comprising converting the compound of formula IV to a compound of formula VII
Figure US20110137056A1-20110609-C00027
5. A process according to claim 4 wherein the compound of formula IV is treated with ammonia in the presence of a suitable base.
6. A process according to claim 1 further comprising preparing the compound of formula III by treating a compound of formula II
Figure US20110137056A1-20110609-C00028
with a base.
7. A process for preparing a compound of formula IV
Figure US20110137056A1-20110609-C00029
wherein R is an alkyl group, comprising:
a) reducing a compound of formula I
Figure US20110137056A1-20110609-C00030
to give a compound of formula II
Figure US20110137056A1-20110609-C00031
b) treating the compound of formula II with a base to give a compound of formula III
Figure US20110137056A1-20110609-C00032
c) treating the compound of formula III with a compound of formula 3
Figure US20110137056A1-20110609-C00033
wherein R1 and R2 are, independently, selected from alkyl.
8. A process according to claim 7 wherein the compound of formula III is triethyl phosphonoacetate.
9. A process according to claim 7 wherein R, R1 and R2 are, independently, selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, and tert-butyl.
10. A process according to claim 7 further comprising converting the compound of formula IV to a compound of formula VII
Figure US20110137056A1-20110609-C00034
11. A process according to claim 10 wherein the compound of formula IV is treated with ammonia in the presence of a suitable base.
12. A process for preparing a compound of formula IV
Figure US20110137056A1-20110609-C00035
wherein R is an alkyl group, comprising:
a) treating the compound of formula II
Figure US20110137056A1-20110609-C00036
with a base; and
b) treating the product of a) with a compound of formula 3
Figure US20110137056A1-20110609-C00037
wherein R1 and R2 are, independently, selected from alkyl.
13. A process according to claim 12 wherein the base is sodium hydroxide.
14. A process according to claim 12 wherein R, R1 and R2 are, independently, selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, and tert-butyl.
15. A process according to claim 12 wherein the compound of formula 3 is triethyl phosphonoacetate.
16. A process according to claim 12 further comprising converting the compound of formula IV to a compound of formula VII
Figure US20110137056A1-20110609-C00038
17. A process according to claim 16 wherein the compound of formula IV is treated with ammonia in the presence of a suitable base.
18. A process for preparing a compound of formula VII
Figure US20110137056A1-20110609-C00039
comprising treating the compound of formula IV
Figure US20110137056A1-20110609-C00040
with ammonia in the presence of a suitable base.
19. A process according to claim 18 wherein the base is sodium methoxide.
20. A process according to claim 18 wherein the base is potassium methoxide.
21. A compound of formula II
Figure US20110137056A1-20110609-C00041
or formula III
Figure US20110137056A1-20110609-C00042
or formula VII
Figure US20110137056A1-20110609-C00043
US12/956,133 2006-08-05 2010-11-30 Chemical Process For Preparation Of Intermediates Abandoned US20110137056A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/956,133 US20110137056A1 (en) 2006-08-05 2010-11-30 Chemical Process For Preparation Of Intermediates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0615619.4A GB0615619D0 (en) 2006-08-05 2006-08-05 Chemical process for preparation of intermediates
GB0615619.4 2006-08-05
US11/833,263 US7863469B2 (en) 2006-08-05 2007-08-03 Chemical process for preparation of intermediates
US12/956,133 US20110137056A1 (en) 2006-08-05 2010-11-30 Chemical Process For Preparation Of Intermediates

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/833,263 Continuation US7863469B2 (en) 2006-08-05 2007-08-03 Chemical process for preparation of intermediates

Publications (1)

Publication Number Publication Date
US20110137056A1 true US20110137056A1 (en) 2011-06-09

Family

ID=37027327

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/833,263 Expired - Fee Related US7863469B2 (en) 2006-08-05 2007-08-03 Chemical process for preparation of intermediates
US12/956,133 Abandoned US20110137056A1 (en) 2006-08-05 2010-11-30 Chemical Process For Preparation Of Intermediates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/833,263 Expired - Fee Related US7863469B2 (en) 2006-08-05 2007-08-03 Chemical process for preparation of intermediates

Country Status (16)

Country Link
US (2) US7863469B2 (en)
EP (1) EP2049462A4 (en)
JP (1) JP2010500343A (en)
KR (1) KR20090045920A (en)
CN (1) CN101495442A (en)
AR (1) AR062148A1 (en)
AU (1) AU2007282181B2 (en)
BR (1) BRPI0714573A2 (en)
CA (1) CA2658953A1 (en)
CL (1) CL2007002267A1 (en)
GB (1) GB0615619D0 (en)
IL (1) IL196233A0 (en)
MX (1) MX2009001020A (en)
MY (1) MY147871A (en)
TW (1) TW200812958A (en)
WO (1) WO2008018822A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120136167A1 (en) * 2006-08-05 2012-05-31 Astrazeneca Ab Processes For The Preparation Of Optically Active Intermediates

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615619D0 (en) * 2006-08-05 2006-09-13 Astrazeneca Ab Chemical process for preparation of intermediates
SG196805A1 (en) 2008-09-09 2014-02-13 Astrazeneca Ab A process for preparing [1s- [1-alpha, 2-alpha, 3-beta (1s*, 2r*) 5-beta] ] -3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino] - 5- (propylthio) -3h-1, 2, 3-triazolo [4, 5-d] pyrimidin-3-yl] -5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates
EP2389372B1 (en) * 2009-01-23 2015-09-09 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2796504A1 (en) 2010-04-20 2011-10-27 Actavis Group Ptc Ehf Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
AU2011273101A1 (en) * 2010-06-30 2013-01-17 Actavis Group Ptc Ehf Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
WO2012063126A2 (en) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
US20130317220A1 (en) 2010-12-20 2013-11-28 Actavis Group Ptc Ehf NOVEL PROCESSES FOR PREPARING TRIAZOLO[4, 5-d]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF
EP2721018A1 (en) 2011-06-15 2014-04-23 Actavis Group Ptc Ehf Improved process for preparing cyclopentylamine derivatives and intermediates thereof
EP2589587A1 (en) 2011-11-04 2013-05-08 Chemo Ibérica, S.A. Synthesis of nitrogen substituted cyclopropanes
EP2628721A1 (en) 2012-02-20 2013-08-21 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanecarboxylic acid
CN104603098B (en) 2012-03-30 2016-06-29 桑多斯股份公司 The synthesis of 2-(3,4-difluorophenyl) cyclopropyl amine derivatives and salt
EP2644590A1 (en) 2012-03-30 2013-10-02 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
EP2834247A4 (en) 2012-04-05 2016-03-30 Reddys Lab Ltd Dr Preparation of ticagrelor
CN102775314A (en) * 2012-08-03 2012-11-14 江苏富泽药业有限公司 Preparation method of trans-(1R, 2S)-2-(3, 4-difluoro phenyl) cyclopropylamine
CN103664697B (en) * 2012-09-07 2016-12-21 博瑞生物医药(苏州)股份有限公司 For preparing the chemical method of aromatic ring propionitrile and cyclopropylamine
CN102863341B (en) * 2012-10-22 2014-05-07 南通大学 Chemical synthesis method of (1R, 2S)-2-aryl cyclopropylamine derivative
CN103073525B (en) * 2013-02-04 2015-01-28 北京科技大学 Method for synthesizing (S)-(3,4-difluorophenyl)hexamethylene oxide
CN103087011A (en) * 2013-02-04 2013-05-08 北京科技大学 Method for preparing (S)-3,4-difluorophenyl oxirane through hydrolytic kinetic resolution
WO2014206187A1 (en) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 Preparation method of ticagrelor and intermediates thereof
CN104974017B (en) * 2014-04-09 2017-11-17 上海医药工业研究院 The preparation method of (1R, 2S) 2 (3,4 difluorophenyl) cyclopropylamine D mandelates
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
PT3154959T (en) 2014-05-15 2019-09-24 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
US10011605B2 (en) 2014-06-18 2018-07-03 Flamma Spa Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds
CN104326922B (en) * 2014-11-03 2016-08-17 成都百裕制药股份有限公司 The preparation method of ticagrelor intermediate (1R, 2S)-2-(2,3-difluorophenyl) cyclopropylamine
TWI579259B (en) * 2014-12-17 2017-04-21 日名國際藥品有限公司 Method of preparing (1r,2s)-2-(3,4-difluorophenyl)-3-r substituted-cyclopropylamine
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105671099A (en) * 2016-01-26 2016-06-15 中国科学院成都生物研究所 Method for preparing optical pure difluorophenyl ethylene oxide
CN106854158B (en) * 2016-12-08 2019-06-14 淮阴工学院 A kind of synthetic method and its intermediate of ticagrelor intermediate
CN106905182A (en) * 2017-01-12 2017-06-30 淮阴工学院 The synthetic method and its intermediate of a kind of ticagrelor intermediate
CN107118141B (en) * 2017-04-18 2018-11-30 淮阴工学院 A kind of synthetic method and its intermediate of ticagrelor intermediate
CN107686447A (en) * 2017-08-25 2018-02-13 许昌恒生制药有限公司 A kind of preparation method of ticagrelor intermediate
CN108083997A (en) * 2017-11-14 2018-05-29 南通常佑药业科技有限公司 A kind of preparation method of chiral aryl cyclopropyl amine derivatives
EP3617181A1 (en) 2018-08-30 2020-03-04 Arevipharma GmbH Synthesis of trans-2-phenylcyclopropylamine or a salt or solvate thereof
CN110437092B (en) * 2019-07-11 2022-06-10 泓博智源(开原)药业有限公司 Preparation method of ticagrelor key intermediate aromatic cyclopropane amide
CN111233673B (en) * 2020-02-26 2022-08-16 苏州元兴生物医药有限公司 Preparation method of chiral aromatic cyclopropylamine and salt thereof and intermediate used in preparation method
CN115894496A (en) * 2021-09-30 2023-04-04 上海贝美医药科技有限公司 Preparation method of ticagrelor and intermediate thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411925A (en) * 1980-01-21 1983-10-25 Pfizer Inc. Branched amides of L-aspartyl-d-amino acid dipeptides
US4590292A (en) * 1985-06-10 1986-05-20 Ciba-Geigy Corporation Process for the manufacture of cyclopropylamine
US4933477A (en) * 1987-09-02 1990-06-12 Basf Aktiengesellschaft Preparation of phenyl-substituted epoxides
US5225602A (en) * 1985-12-11 1993-07-06 Basf Aktiengesellschaft Phenylacetaldehydes and the preparation of phenylacetaldehydes
US5672504A (en) * 1993-02-15 1997-09-30 Daicel Chemical Industries, Ltd. Process for enriching an R,S!-1,2-epoxide in one enantiomer by using microbes to convert one enantiomer to the other or to preferentially open the epoxide ring
US6552217B2 (en) * 2000-08-01 2003-04-22 Eastman Chemical Company Process for the preparation of alkyl 1-methylcyclopropanecarboxylate
US6683216B1 (en) * 2002-11-06 2004-01-27 Eastman Chemical Company Continuous process for the preparation of amines
US20080071114A1 (en) * 2006-08-05 2008-03-20 Astrazeneca Ab Processes For The Preparation Of Optically Active Intermediates
US7863469B2 (en) * 2006-08-05 2011-01-04 Astrazeneca Ab Chemical process for preparation of intermediates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909142A1 (en) 1989-03-21 1990-10-04 Basf Ag METHOD FOR PRODUCING AMINES
DE4315623A1 (en) 1993-05-11 1994-11-17 Hoechst Ag Process for the preparation of amines
DE4400328A1 (en) * 1994-01-07 1995-07-13 Huels Chemische Werke Ag Process for the preparation of cyclopropanecarboxamide
DE19523868A1 (en) 1995-06-30 1997-01-02 Huels Chemische Werke Ag Cyclopropanamine prodn. by Hofmann degradation of cyclopropane-carboxamide
DE19547635A1 (en) * 1995-12-20 1997-06-26 Bayer Ag Process for the preparation of cyclopropanecarboxamides
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
AR028110A1 (en) * 2000-06-02 2003-04-23 Astrazeneca Ab NEW PROCESS

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411925A (en) * 1980-01-21 1983-10-25 Pfizer Inc. Branched amides of L-aspartyl-d-amino acid dipeptides
US4590292A (en) * 1985-06-10 1986-05-20 Ciba-Geigy Corporation Process for the manufacture of cyclopropylamine
US5225602A (en) * 1985-12-11 1993-07-06 Basf Aktiengesellschaft Phenylacetaldehydes and the preparation of phenylacetaldehydes
US4933477A (en) * 1987-09-02 1990-06-12 Basf Aktiengesellschaft Preparation of phenyl-substituted epoxides
US5672504A (en) * 1993-02-15 1997-09-30 Daicel Chemical Industries, Ltd. Process for enriching an R,S!-1,2-epoxide in one enantiomer by using microbes to convert one enantiomer to the other or to preferentially open the epoxide ring
US6552217B2 (en) * 2000-08-01 2003-04-22 Eastman Chemical Company Process for the preparation of alkyl 1-methylcyclopropanecarboxylate
US6683216B1 (en) * 2002-11-06 2004-01-27 Eastman Chemical Company Continuous process for the preparation of amines
US20080071114A1 (en) * 2006-08-05 2008-03-20 Astrazeneca Ab Processes For The Preparation Of Optically Active Intermediates
US7790927B2 (en) * 2006-08-05 2010-09-07 Astrazeneca Ab Processes for the preparation of optically active intermediates
US20100331575A1 (en) * 2006-08-05 2010-12-30 Astrazeneca Ab Processes For The Preparation Of Optically Active Intermediates
US7863469B2 (en) * 2006-08-05 2011-01-04 Astrazeneca Ab Chemical process for preparation of intermediates
US8026396B2 (en) * 2006-08-05 2011-09-27 Astrazeneca Ab Processes for the preparation of optically active intermediates

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120136167A1 (en) * 2006-08-05 2012-05-31 Astrazeneca Ab Processes For The Preparation Of Optically Active Intermediates
US8278475B2 (en) * 2006-08-05 2012-10-02 Astrazeneca Ab Processes for the preparation of optically active intermediates

Also Published As

Publication number Publication date
AU2007282181B2 (en) 2012-04-19
CL2007002267A1 (en) 2008-04-04
EP2049462A4 (en) 2012-06-13
IL196233A0 (en) 2009-09-22
CN101495442A (en) 2009-07-29
US7863469B2 (en) 2011-01-04
KR20090045920A (en) 2009-05-08
WO2008018822A1 (en) 2008-02-14
JP2010500343A (en) 2010-01-07
MY147871A (en) 2013-01-31
US20080132719A1 (en) 2008-06-05
BRPI0714573A2 (en) 2013-06-04
TW200812958A (en) 2008-03-16
AR062148A1 (en) 2008-10-15
CA2658953A1 (en) 2008-02-14
EP2049462A1 (en) 2009-04-22
AU2007282181A1 (en) 2008-02-14
MX2009001020A (en) 2009-02-05
GB0615619D0 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
US20110137056A1 (en) Chemical Process For Preparation Of Intermediates
US20100228028A1 (en) Processes for the manufacture of rosuvastatin and intermediates
KR101019450B1 (en) Diastereomeric purification of rosuvastatin
US20120130097A1 (en) Process for the preparation of cyclopropyl carboxylic acid esters and derivatives
ZA200405250B (en) Methods for preparing o-desmethylvenlafaxine
US20220298099A1 (en) Synthesis of omecamtiv mecarbil
US10738058B2 (en) Method of manufacturing 4-chloro-7H-pyrrolo[2,3-D]pyrimidine
AU2018366342A1 (en) Method for preparing Baricitinib
CN110294716B (en) Preparation method of azoxystrobin and intermediate thereof
US7868169B2 (en) Crystalline rosuvastatin intermediate
US8455700B2 (en) Method for producing phenylalkane-1-ols
CN111004121A (en) Preparation method of 4-alkoxy acetoacetic ester compound
US6605720B1 (en) Process for making spirolactone compounds
US20070185352A1 (en) New process for the dimerisation of alkyl glyoxals
CN1197841C (en) Process for producing halogenated phenyl malonic ester
JP4032861B2 (en) Process for producing β-oxonitrile derivative or alkali metal salt thereof
US20050171349A1 (en) Method for producing n-ethyl-n-{3-(3-cyanopyrazolo{1,5a}pyrimidine-7-yl)phenyl acetamide
EP2161270A1 (en) Gemifloxacin hydrates
EP3530645B1 (en) Method for producing nitrogen-containing compound
US20230265062A1 (en) 4-furanamides and method for the production thereof
AU2012201783A1 (en) Chemical process for preparation of aromatic cyclopropane esters and amides
JP2000309595A (en) Production of n-[5-(diphenylphosphinoylmethyl)-4-(4- fluorophenyl)-6-isopropylpyrimidin-2-yl-n- methylmethanesulphonamide
WO2005023813A1 (en) Zaleplon synthesis
EP1502907A1 (en) A process for the preparation of (2-hydroxymethyl-phenyl)-phenyl-methanol derivatives
JP2000264878A (en) Production of 1-[(cyclopent-3-en-1-yl)methyl]-5-ethyl-6-(3,5- dimethylbenzoyl)-2,4-pyrimidinedione

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER FROM 11/833,263 PREVIOUSLY RECORDED ON REEL 025853 FRAME 0251. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT APPLICATION NUMBER IS 12/956133;ASSIGNORS:DEJONGHE, JEAN-PAUL;PEETERS, KOEN;RENARD, MARC;SIGNING DATES FROM 20070629 TO 20070703;REEL/FRAME:026028/0539

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION